SIGLEC1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: SIGLEC1

NCBI ID: G6614

SIGLEC1

SIGLEC1: A Potential Drug Target and Biomarker for Various Diseases

SIGLEC1 (solute carrier family 1 member 1) is a protein that is expressed in various tissues throughout the body. It is a transmembrane protein that is involved in the transport of a variety of substances, including small molecules, ions, and water across cell membranes. SIGLEC1 is also known as SN (sodium channels), and it is a potential drug target and biomarker for various diseases.

SIGLEC1 is a member of the solute carrier family 1, which is a large family of transmembrane proteins that play a key role in the transport of solutes and other molecules across cell membranes. This family of proteins includes proteins that are involved in the transport of a variety of different substances, including ions, small molecules, and water. SIGLEC1 is specifically involved in the transport of sodium ions across cell membranes.

SIGLEC1 is a transmembrane protein that is expressed in a variety of tissues throughout the body, including the brain, heart, liver, and kidneys. It is primarily located in the cell membrane, where it is involved in the transport of sodium ions across the membrane. SIGLEC1 helps to regulate the movement of sodium ions into and out of cells, which is important for maintaining the proper levels of electrical activity in the body.

SIGLEC1 is a potential drug target for a variety of diseases. For example, it is known to be involved in the development of hypertension, which is a common condition that can lead to a range of health problems, including heart disease, stroke, and kidney damage. Studies have shown that SIGLEC1 is involved in the regulation of sodium ion transport in the brain, and that it may play a role in the development of hypertension.

In addition to its potential role in hypertension, SIGLEC1 is also a potential biomarker for several other diseases. For example, it is often used as a biomarker for heart failure, as it is involved in the regulation of sodium ion transport in the heart. It is also used as a biomarker for liver disease, as it is involved in the transport of nutrients and waste products across the liver membrane.

SIGLEC1 is also a potential target for drug development for other diseases. For example, studies have shown that inhibiting SIGLEC1 function can be effective in treating certain types of cancer, as it can help to inhibit the spread of cancer cells across cell membranes. Additionally, SIGLEC1 is also a potential target for treating certain neurological disorders, such as Alzheimer's disease and Parkinson's disease, as it is involved in the regulation of sodium ion transport in the brain.

Overall, SIGLEC1 is a transmembrane protein that is involved in the transport of various substances across cell membranes, including sodium ions. It is a potential drug target and biomarker for a variety of diseases, including hypertension, heart failure, liver disease, and cancer. Further research is needed to fully understand the role of SIGLEC1 in these diseases and to develop effective treatments.

Protein Name: Sialic Acid Binding Ig Like Lectin 1

Functions: Macrophage-restricted adhesion molecule that mediates sialic-acid dependent binding to lymphocytes, including granulocytes, monocytes, natural killer cells, B-cells and CD8 T-cells. Plays a crucial role in limiting bacterial dissemination by engaging sialylated bacteria to promote effective phagocytosis and antigen presentation for the adaptive immune response (PubMed:12940982, PubMed:33489013). Mediates the uptake of various enveloped viruses via sialic acid recognition and subsequently induces the formation of intracellular compartments filled with virions (VCCs)(PubMed:28129379). In turn, enhances macrophage-to-T-cell transmission of several viruses including HIV-1 or SARS-CoV-2 (PubMed:28129379, PubMed:34782760). Acts as an endocytic receptor mediating clathrin dependent endocytosis. Preferentially binds to alpha-2,3-linked sialic acid (PubMed:12940982). Binds to SPN/CD43 on T-cells (By similarity). May play a role in hemopoiesis. Plays a role in the inhibition of antiviral innate immune by promoting TBK1 degradation via TYROBP and TRIM27-mediated ubiquitination (PubMed:26358190)

The "SIGLEC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIGLEC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets